Pre-clinical studies using SphK1-targeting therapies have shown that they possess anticancer activity, and recent findings have demonstrated that co-treatment with an epidermal growth factor receptor (EGFR) targeted therapy, gefitinib, and SphK1-targeted therapy has clinical potential in breast cancer [21–24]. The gene discussed is EGFR; the disease is breast cancer.